logo-loader
viewe-Therapeutics plc

Danish drugs giant Novo Nordisk to use e-Therapeutics’ technology in search for new diabetes treatments

e-Therapeutics will be reimbursed for its work under this collaboration and Novo Nordisk has the option to license relevant IP generated under the collaboration

diabetes
Novo Nordisk is predominantly focused on diabetes

The world’s largest producer of insulin is to use e-Therapeutics PLC’s (LON:ETX) Network-Driven Drug Discovery (NDD) platform as it looks to discover new ways of treating type-2 diabetes.

Type-2 diabetes primarily occurs as a result of lack of exercise and obesity and is thought to account for around 90% of the 425mln people with diabetes around the world.

Scientists have been tasked with finding new treatments in order to tackle the growing incidence of the condition.

READ: ETX and C4X team up to find new Parkinson’s treatments

As part of the tie-up, Danish pharma giant Novo Nordisk will use ETX’s NDD approach to identify novel intervention strategies, biological pathways and compounds for testing that could potentially form the basis of novel therapies.

e-Therapeutics will be reimbursed for its work under this collaboration and Novo Nordisk has the option to license relevant IP generated under the collaboration.

Any future license would require mutual agreement of commercial terms. Financial details of the collaboration have not been disclosed.

 “We are delighted to be working with Novo Nordisk, a world leader and innovator in diabetes care,” said ETX chief executive Ray Barlow.

“This collaboration highlights the use of our Network-Driven Drug Discovery (NDD) platform to understand and potentially create new treatments for complex diseases of great relevance to society, medicine and the industry.”

“Our new collaboration with Novo Nordisk is the result of a systematic and rigorous business development exercise over the past year and we hope to announce a number of additional collaborations during the course of 2019.”

Novo Nordisk’s head of bioinformatics, Jan Nygaard Jensen, added: “We are looking forward to cooperating with e-therapeutics. It is an exciting technology and we will investigate if it can support some of the early target discovery efforts we are building in Novo Nordisk Research Center Oxford.”

Quick facts: e-Therapeutics plc

Price: 3 GBX

AIM:ETX
Market: AIM
Market Cap: £8.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

3 weeks ago

Holding(s) in Company

3 weeks, 1 day ago

Holding(s) in Company

3 weeks, 1 day ago

Holding(s) in Company

3 weeks, 1 day ago

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read